EvoEndo Revenue and Competitors
Estimated Revenue & Valuation
- EvoEndo's total funding is $19M.
Employee Data
- EvoEndo has 20 Employees.
- EvoEndo grew their employee count by 11% last year.
EvoEndo's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | President and CEO | Reveal Email/Phone |
3 | Co-Founder | Reveal Email/Phone |
4 | Chief Operating Officer | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Sr VP Manufacturing and Operations | Reveal Email/Phone |
7 | Regional Sales and Market Development Director Eastern United States | Reveal Email/Phone |
8 | National Sales Director | Reveal Email/Phone |
9 | Senior Director Marketing & Communications | Reveal Email/Phone |
10 | Regional Sales & Market Development Director | Reveal Email/Phone |
EvoEndo Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $75M | 788 | 0% | N/A | N/A |
#2 | $3.5M | 14 | 0% | N/A | N/A |
#3 | N/A | 20 | 5% | N/A | N/A |
#4 | $15M | 40 | 5% | N/A | N/A |
#5 | N/A | 36 | 38% | N/A | N/A |
#6 | N/A | 768 | 6% | N/A | N/A |
#7 | N/A | 9 | 13% | N/A | N/A |
#8 | N/A | 32 | 23% | N/A | N/A |
#9 | $3.5M | 32 | 0% | N/A | N/A |
#10 | $35M | 334 | 9% | N/A | N/A |
What Is EvoEndo?
EvoEndo’s Single-Use Endoscopy System allows patients five and older to undergo a transnasal EGD exam without anesthesia or sedation. EvoEndo’s ultra-slim gastroscope, virtual reality patient distraction, and comprehensive training program are specifically designed to help physicians and hospitals start and grow a TNE program in their practice, providing an unsedated alternative to upper endoscopy for patients and their families.
keywords:N/A$19M
Total Funding
20
Number of Employees
N/A
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.8M | 20 | N/A | N/A |
#2 | $2M | 20 | N/A | N/A |
#3 | $4.1M | 20 | 11% | N/A |
#4 | $4.1M | 20 | -29% | N/A |
#5 | $2.1M | 21 | N/A | N/A |